Bristol-Myers Squibb (BMY)
49.23
-0.13 (-0.26%)
At close: Apr 17, 2025, 3:59 PM
49.49
0.54%
After-hours: Apr 17, 2025, 07:58 PM EDT
Bristol-Myers Squibb Revenue Breakdown
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abecma Revenue | 132M | 147M | 125M | 107M | 89M | 67M | 69M | 71M | 24M | 314M | 297M | 342M | 308M | 300M | 2.03B | 1.93B | 2.04B | 1.93B | 1.71B | 1.58B | 1.65B | 1.51B | 1.36B | 1.23B | 1.18B | 1.1B | 948M | 884M | 777M | 734M | 602M | 466M | 437M | 355M | 281M | 216M | 171M | 106M | 134M | 375M | 12M |
| Abecma Revenue Growth | -10.20% | +17.60% | +16.82% | +20.22% | +32.84% | -2.90% | -2.82% | +195.83% | -92.36% | +5.72% | -13.16% | +11.04% | +2.67% | -85.25% | +5.50% | -5.58% | +6.08% | +12.90% | +8.12% | -4.42% | +9.56% | +10.49% | +10.63% | +4.76% | +6.81% | +16.14% | +7.24% | +13.77% | +5.86% | +21.93% | +29.18% | +6.64% | +23.10% | +26.33% | +30.09% | +26.32% | +61.32% | -20.90% | -64.27% | +3025.00% | n/a |
| Abraxane Revenue | 258M | 239M | 179M | 177M | 241M | 214M | 305M | 266M | 296M | 2.89B | 2.27B | 2.1B | 2.16B | 2.64B | 1.76B | 1.82B | 1.82B | 1.8B | 1.8B | 1.79B | 1.63B | 1.51B | 1.36B | 1.26B | 1.2B | 1.13B | 1.31B | 920M | 840M | 704M | 475M | 305M | 122M | 40M | 5M | 1M | 402M | 363M | 717M | 316M | 352M |
| Abraxane Revenue Growth | +7.95% | +33.52% | +1.13% | -26.56% | +12.62% | -29.84% | +14.66% | -10.14% | -89.74% | +27.19% | +8.31% | -3.14% | -18.10% | +49.80% | -2.97% | -0.33% | +1.22% | -0.17% | +0.61% | +10.20% | +7.68% | +11.02% | +7.59% | +5.86% | +6.03% | -13.97% | +42.39% | +9.52% | +19.32% | +48.21% | +55.74% | +150.00% | +205.00% | +700.00% | +400.00% | -99.75% | +10.74% | -49.37% | +126.90% | -10.23% | n/a |
| Breyanzi Revenue | 100M | 71M | 55M | 44M | 39M | 44M | 40M | 30M | 17M | 16M | 15M | 13M | 15M | 12M | 792M | 767M | 778M | 640M | 731M | 675M | 711M | 593M | 662M | 632M | 650M | 535M | 625M | 572M | 593M | 475M | 540M | 484M | 461M | 400M | 443M | 444M | 368M | 342M | 652M | 238M | 312M |
| Breyanzi Revenue Growth | +40.85% | +29.09% | +25.00% | +12.82% | -11.36% | +10.00% | +33.33% | +76.47% | +6.25% | +6.67% | +15.38% | -13.33% | +25.00% | -98.48% | +3.26% | -1.41% | +21.56% | -12.45% | +8.30% | -5.06% | +19.90% | -10.42% | +4.75% | -2.77% | +21.50% | -14.40% | +9.27% | -3.54% | +24.84% | -12.04% | +11.57% | +4.99% | +15.25% | -9.71% | -0.23% | +20.65% | +7.60% | -47.55% | +173.95% | -23.72% | n/a |
| Camzyos Revenue | 46M | 29M | 16M | 5M | 3M | 3.21B | 2.67B | 2.41B | 2.79B | 15M | 14M | 3M | 1.65B | 1.77B | 549M | 558M | 544M | 459M | 536M | 491M | 535M | 438M | 527M | 509M | 506M | 463M | 494M | 472M | 451M | 407M | 429M | 411M | 405M | 375M | 398M | 385M | 321M | 271M | 489M | n/a | 233M |
| Camzyos Revenue Growth | +58.62% | +81.25% | +220.00% | +66.67% | -99.91% | +20.22% | +10.69% | -13.57% | +18513.33% | +7.14% | +366.67% | -99.82% | -6.40% | +221.68% | -1.61% | +2.57% | +18.52% | -14.37% | +9.16% | -8.22% | +22.15% | -16.89% | +3.54% | +0.59% | +9.29% | -6.28% | +4.66% | +4.66% | +10.81% | -5.13% | +4.38% | +1.48% | +8.00% | -5.78% | +3.38% | +19.94% | +18.45% | -44.58% | n/a | n/a | n/a |
| Eliquis Revenue | 3.2B | 3.42B | 2.69B | 2.65B | 3.23B | 18M | 20M | 22M | 16M | 1.72B | 1.79B | 1.78B | 750M | 714M | 385M | 353M | 367M | 384M | 384M | 382M | 315M | 249M | 269M | 323M | 322M | 330M | 264M | 285M | 241M | 263M | 265M | 240M | 296M | 325M | 366M | 350M | n/a | n/a | n/a | n/a | n/a |
| Eliquis Revenue Growth | -6.40% | +27.34% | +1.24% | -17.93% | +17872.22% | -10.00% | -9.09% | +37.50% | -99.07% | -4.07% | +0.73% | +137.33% | +5.04% | +85.45% | +9.07% | -3.81% | -4.43% | 0.00% | +0.52% | +21.27% | +26.51% | -7.43% | -16.72% | +0.31% | -2.42% | +25.00% | -7.37% | +18.26% | -8.37% | -0.75% | +10.42% | -18.92% | -8.92% | -11.20% | +4.57% | n/a | n/a | n/a | n/a | n/a | n/a |
| Inrebic Revenue | 27M | 25M | 23M | 21M | 23M | 23M | 25M | 21M | 12M | 758M | 867M | 826M | 745M | 713M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Inrebic Revenue Growth | +8.00% | +8.70% | +9.52% | -8.70% | 0.00% | -8.00% | +19.05% | +75.00% | -98.42% | -12.57% | +4.96% | +10.87% | +4.49% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Onureg Revenue | 44M | 34M | 37M | 32M | 32M | 1.92B | 1.99B | 1.91B | 1.91B | 773M | 835M | 777M | 55M | 8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Onureg Revenue Growth | +29.41% | -8.11% | +15.62% | 0.00% | -98.34% | -3.27% | +4.36% | -0.26% | +147.09% | -7.43% | +7.46% | +1312.73% | +587.50% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdivo Revenue | 2.15B | 2.2B | 2.22B | 2.05B | 2.06B | 6M | 864M | 870M | 814M | 112M | 115M | 96M | 2.88B | 2.92B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdivo Revenue Growth | -2.59% | -0.63% | +8.26% | -0.78% | +34283.33% | -99.31% | -0.69% | +6.88% | +626.79% | -2.61% | +19.79% | -96.67% | -1.06% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdualag Revenue | 154M | 117M | 104M | 84M | 58M | 792M | 854M | 851M | 854M | 2.94B | 3.28B | 3.03B | 511M | 521M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdualag Revenue Growth | +31.62% | +12.50% | +23.81% | +44.83% | -92.68% | -7.26% | +0.35% | -0.35% | -70.99% | -10.24% | +8.36% | +492.37% | -1.92% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Orencia Revenue | 927M | 764M | 913M | 883M | 876M | 826M | 151M | 160M | 128M | 470M | 564M | 544M | 369M | 396M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Orencia Revenue Growth | +21.34% | -16.32% | +3.40% | +0.80% | +6.05% | +447.02% | -5.62% | +25.00% | -72.77% | -16.67% | +3.68% | +47.43% | -6.82% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pomalyst/Imnovid Revenue | 847M | 832M | 877M | 886M | 908M | 156M | 3.33B | 3.35B | 3.2B | 456M | 471M | 446M | 1M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pomalyst/Imnovid Revenue Growth | +1.80% | -5.13% | -1.02% | -2.42% | +482.05% | -95.31% | -0.57% | +4.53% | +602.19% | -3.18% | +5.61% | +44500.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Reblozyl Revenue | 234M | 206M | 199M | 190M | 172M | 2.8B | 555M | 551M | 541M | 18M | 9M | 2M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Reblozyl Revenue Growth | +13.59% | +3.52% | +4.74% | +10.47% | -93.85% | +403.96% | +0.73% | +1.85% | +2905.56% | +100.00% | +350.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Revlimid Revenue | 1.47B | 1.75B | 2.26B | 2.42B | 2.5B | 483M | 545M | 515M | 510M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Revlimid Revenue Growth | -16.11% | -22.57% | -6.61% | -3.24% | +417.81% | -11.38% | +5.83% | +0.98% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sotyktu Revenue | 25M | 16M | 7M | 1M | 544M | 515M | 48M | 40M | 28M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sotyktu Revenue Growth | +56.25% | +128.57% | +600.00% | -99.82% | +5.63% | +972.92% | +20.00% | +42.86% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sprycel Revenue | 458M | 429M | 578M | 560M | 525M | 36M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sprycel Revenue Growth | +6.76% | -25.78% | +3.21% | +6.67% | +1358.33% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Yervoy Revenue | 585M | 508M | 568M | 523M | 66M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Yervoy Revenue Growth | +15.16% | -10.56% | +8.60% | +692.42% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Zeposia Revenue | 100M | 78M | 79M | 69M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Zeposia Revenue Growth | +28.21% | -1.27% | +14.49% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 13.5B | 10.69B | 9.85B | 6.27B | 5.66B | 4.99B | 4.21B | 3.49B | 3.59B | 3.93B | 3.45B |
| Europe Revenue Growth | +26.29% | +8.46% | +57.25% | +10.75% | +13.43% | +18.34% | +20.74% | -2.81% | -8.60% | +13.98% | n/a |
| Other Region Revenue | 834M | 852M | 631M | 524M | 584M | 553M | 528M | 739M | 1.11B | 842M | n/a |
| Other Region Revenue Growth | -2.11% | +35.02% | +20.42% | -10.27% | +5.61% | +4.73% | -28.55% | -33.54% | +32.07% | n/a | n/a |
| United States Revenue | 31.83B | 29.21B | 26.58B | 15.34B | 12.59B | 11.36B | 10.72B | 8.19B | 7.72B | 8.32B | n/a |
| United States Revenue Growth | +8.95% | +9.92% | +73.23% | +21.90% | +10.81% | +5.95% | +30.92% | +6.12% | -7.24% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.14B | 1.98B | 1.92B | 2.37B | 2.07B | 2B | 1.93B | 1.76B | 2.27B | 1.93B | 1.79B | 1.83B | 2.35B | 1.79B | 1.88B | 1.67B | 2.72B | 1.71B | 1.63B | 1.61B | 1.73B | 1.05B | 1.08B | 1.01B | 1.34B | 1.1B | 1.13B | 980M | 1.37B | 1.17B | 1.2B | 1.11B | 1.49B | 1.16B | 1.26B | 1.09B | 1.55B | 1.22B | 1.17B | 1.06B |
| Selling, General, and Administrative Revenue Growth | +7.72% | +3.17% | -18.80% | +14.18% | +3.49% | +3.57% | +9.76% | -22.24% | +17.41% | +8.00% | -2.40% | -22.22% | +31.66% | -4.99% | +12.97% | -38.77% | +59.50% | +4.79% | +1.37% | -7.38% | +64.36% | -1.95% | +6.96% | -24.70% | +21.01% | -2.39% | +15.41% | -28.47% | +17.19% | -2.83% | +8.67% | -25.50% | +27.77% | -7.92% | +15.87% | -29.68% | +26.63% | +4.53% | +10.89% | n/a |
| Research and Development Revenue | 3.22B | 2.37B | 2.29B | 2.69B | 2.48B | 2.24B | 2.26B | 2.32B | 2.51B | 2.42B | 2.32B | 2.26B | 2.52B | 3.25B | 3.27B | 2.23B | 3.75B | 2.5B | 2.52B | 2.37B | 2.1B | 1.38B | 1.33B | 1.35B | 1.38B | 1.28B | 2.44B | 1.25B | 1.92B | 1.54B | 1.66B | 1.29B | 1.4B | 1.14B | 1.27B | 1.14B | 1.92B | 1.13B | 1.86B | 1.02B |
| Research and Development Revenue Growth | +35.68% | +3.44% | -14.84% | +8.76% | +10.53% | -0.71% | -2.71% | -7.53% | +3.80% | +4.18% | +2.70% | -10.25% | -22.55% | -0.61% | +47.01% | -40.67% | +50.06% | -0.91% | +6.32% | +13.11% | +51.74% | +4.07% | -1.70% | -2.10% | +7.81% | -47.43% | +94.80% | -34.93% | +24.50% | -6.99% | +28.80% | -8.00% | +23.02% | -10.11% | +11.44% | -40.71% | +69.26% | -39.01% | +82.68% | n/a |
| Sales and Marketing Revenue | 1.5B | 1.98B | n/a | 2.37B | 1.4B | 2B | n/a | 1.76B | 2.27B | 1.93B | n/a | n/a | 2.35B | 1.79B | n/a | 1.67B | 2.72B | 1.71B | 1.63B | 1.61B | 1.73B | 1.05B | 1.08B | 1.01B | 1.34B | 1.1B | 1.13B | 980M | 1.3B | 1.15B | 1.17B | 1.07B | 1.46B | 1.14B | 1.24B | 1.07B | 1.5B | 1.18B | 1.14B | 1.03B |
| Sales and Marketing Revenue Growth | -24.36% | n/a | -100.00% | +69.07% | -30.10% | n/a | -100.00% | -22.24% | +17.41% | n/a | n/a | -100.00% | +31.66% | n/a | -100.00% | -38.77% | +59.50% | +4.79% | +1.37% | -7.38% | +64.36% | -1.95% | +6.96% | -24.70% | +21.01% | -2.39% | +15.41% | -24.56% | +13.25% | -1.71% | +8.66% | -26.49% | +27.71% | -7.59% | +15.92% | -28.85% | +27.64% | +3.61% | +10.30% | n/a |